The soft tissue sarcoma treatment landscape is undergoing a fundamental shift as research moves beyond traditional chemotherapy toward targeted, molecular-level interventions. In 2025, the market was valued at USD 310 million, with the United States representing 85% of that total. As incidence rates climb—reaching approximately 40,000 new cases annually across the 7MM—the demand for more effective, durable treatment options has intensified.

Pharmaceutical developers are increasingly focusing on the biological complexity of the disease, including fusion-driven sarcomas and CDK4/MDM2-amplified liposarcoma. High-profile candidates currently in clinical evaluation include TBI-1301 (mipetresgene autoleucel) from Takara Bio, INT230-6 by Intensity Therapeutics, and ZEPZELCA (lurbinectedin), a PharmaMar and Jazz Pharmaceuticals collaboration expected to reach the U.S. market by 2028. These emerging modalities, alongside advancements in immune checkpoint inhibitors and adoptive T-cell therapies, are expected to redefine the standard of care for patients facing advanced or metastatic disease.